Alpha Tau Medical Ltd./$DRTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Ticker
$DRTS
Sector
Primary listing
Employees
125
Headquarters
Jerusalem, Israel
Website
DRTS Metrics
BasicAdvanced
$321M
-
-$0.48
1.00
-
Price and volume
Market cap
$321M
Beta
1
52-week high
$4.69
52-week low
$2.30
Average daily volume
66K
Financial strength
Current ratio
10.517
Quick ratio
9.772
Long term debt to equity
14.123
Total debt to equity
15.37
Interest coverage (TTM)
-121.82%
Profitability
EBITDA (TTM)
-36.445
Effective tax rate (TTM)
-0.47%
Management effectiveness
Return on assets (TTM)
-22.66%
Return on equity (TTM)
-43.83%
Valuation
Price to book
3.71
Price to tangible book (TTM)
3.71
Price to free cash flow (TTM)
-10.215
Free cash flow yield (TTM)
-9.79%
Free cash flow per share (TTM)
-0.37
Growth
Earnings per share change (TTM)
21.97%
3-year earnings per share growth (CAGR)
-13.08%
Bulls say / Bears say
Interim analyses presented at the 2025 ASCO GI Symposium showed up to 100% disease control rates and positive safety profiles across multiple Alpha DaRT® pancreatic cancer trials, underscoring strong local tumor efficacy in a high-unmet-need indication (Nasdaq).
The FDA approved an Investigational Device Exemption to initiate U.S. pilot studies of Alpha DaRT in newly diagnosed pancreatic cancer and immunocompromised patients with recurrent cutaneous squamous cell carcinoma, marking key regulatory progress in major oncology markets (Nasdaq).
A year-end cash balance of $62.9 million provides an estimated two-year operational runway to fund ongoing trials and planned commercial scale-up, supporting progress toward pivotal data readouts and market entry (Nasdaq).
The company reported a net loss of $31.8 million for the year ended December 31, 2024, up from $29.2 million in 2023, highlighting widening operating deficits as it advances its clinical programs (Nasdaq).
Research and development expenses rose to $27.0 million in 2024 and marketing spend increased to $2.3 million, contributing to a high cash burn rate that elevates dilution risk before commercial revenues begin (Nasdaq).
Cash and cash equivalents fell from $84.9 million at December 31, 2023 to $62.9 million at December 31, 2024, demonstrating significant runway erosion and reliance on future financings for continued operations (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alpha Tau Medical Ltd. stock?
Alpha Tau Medical Ltd. (DRTS) has a market cap of $321M as of October 12, 2025.
What is the P/E ratio for Alpha Tau Medical Ltd. stock?
The price to earnings (P/E) ratio for Alpha Tau Medical Ltd. (DRTS) stock is 0 as of October 12, 2025.
Does Alpha Tau Medical Ltd. stock pay dividends?
No, Alpha Tau Medical Ltd. (DRTS) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Alpha Tau Medical Ltd. dividend payment date?
Alpha Tau Medical Ltd. (DRTS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alpha Tau Medical Ltd.?
Alpha Tau Medical Ltd. (DRTS) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.